Business Description
Lagis Enterprise Co Ltd
ISIN : TW0006730005
Share Class Description:
ROCO:6730: Ordinary SharesDescription
Lagis Enterprise Co Ltd is a medical device development company that designs, patents, and markets medical devices for the laparoscopic and endoscopic surgical markets. Its product portfolio includes Access, Endo Devices, Specimen Retrieval products, Suction Irrigation systems, Training systems, and accessories.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.27 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | 2.09 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.62 | |||||
Beneish M-Score | -2.54 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.6 | |||||
3-Year EBITDA Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 25.2 | |||||
3-Year Book Growth Rate | 4.6 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 72.68 | |||||
9-Day RSI | 61.85 | |||||
14-Day RSI | 56.46 | |||||
6-1 Month Momentum % | -2.62 | |||||
12-1 Month Momentum % | 2.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.58 | |||||
Quick Ratio | 0.9 | |||||
Cash Ratio | 0.37 | |||||
Days Inventory | 186.23 | |||||
Days Sales Outstanding | 30.66 | |||||
Days Payable | 28.36 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.56 | |||||
Dividend Payout Ratio | 0.8 | |||||
3-Year Dividend Growth Rate | 6.3 | |||||
Forward Dividend Yield % | 2.56 | |||||
5-Year Yield-on-Cost % | 2.6 | |||||
Shareholder Yield % | -13.53 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 47.55 | |||||
Operating Margin % | 18.36 | |||||
Net Margin % | 15.36 | |||||
FCF Margin % | -27.68 | |||||
ROE % | 13.73 | |||||
ROA % | 8.65 | |||||
ROIC % | 10.19 | |||||
3-Year ROIIC % | 8.36 | |||||
ROC (Joel Greenblatt) % | 15.52 | |||||
ROCE % | 13.57 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 17.36 | |||||
PE Ratio without NRI | 17.36 | |||||
Price-to-Owner-Earnings | 54.1 | |||||
PS Ratio | 2.67 | |||||
PB Ratio | 2.29 | |||||
Price-to-Tangible-Book | 2.31 | |||||
Price-to-Operating-Cash-Flow | 9.61 | |||||
EV-to-EBIT | 15.81 | |||||
EV-to-EBITDA | 11.7 | |||||
EV-to-Revenue | 3.03 | |||||
EV-to-FCF | -10.6 | |||||
Price-to-Projected-FCF | 1.71 | |||||
Price-to-Graham-Number | 1.33 | |||||
Earnings Yield (Greenblatt) % | 6.33 | |||||
FCF Yield % | -10.5 | |||||
Forward Rate of Return (Yacktman) % | -1.51 |